Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma

Trial Profile

Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 May 2018

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Uveal melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Jan 2018 Planned number of patients changed from 52 to 39.
    • 18 Aug 2017 Planned End Date changed from 1 Nov 2018 to 1 Nov 2019.
    • 18 Aug 2017 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top